Actualités Bavarian Nordic AS (PK) - BVNRY | Actions OTCMarkets

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Withdrawal of Registration Statement (rw)

Bavarian Nordic A/S Hejreskovvej 10A DK-3490 Kvistgaard Denmark ...

Securities Registration (foreign Private Issuer) (f-1/a)

Use these links to rapidly review the document TABLE OF CONTENTS BAVARIAN NORDIC A/S INDEX TO...

Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)

As filed with the United States Securities and Exchange Commission on January 5, 2016 Registration No. 333-188749...

EDISON EQUITY RESEARCH - BAVARIAN NORDIC

EDISON EQUITY RESEARCH: BAVARIAN NORDIC – ADR OUTLOOK The BMS and J&J deals, and continued Imvamune related income have provided...

Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Can...

Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development...

EDISON EQUITY RESEARCH - BAVARIAN NORDIC

EDISON EQUITY RESEARCH: BAVARIAN NORDIC - STRATEGIC EBOLDA DEAL FILLS 2015 REVENUE GAP Bavarian Nordic’s $187m exclusive global licensing...

Bavarian Nordic Announces First Patient Treated in a Phase 1 Study of MVA-BN(r) Brachyury in Advanced Cancer

KVISTGAARD, Denmark, July 24, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that the first patient has been...

Bavarian Nordic Announces Appointment of Paul Chaplin, Ph.D. as President & CEO

KVISTGAARD, Denmark, May 28, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today that Paul Chaplin, Ph.D. has...

Bavarian Nordic to Present Data Combining Its Cancer Immunotherapies With Immune Checkpoint Inhibitors at the 2014 ASCO Annua...

KVISTGAARD, Denmark, May 15, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today two papers featuring the...

Bavarian Nordic Announces First Quarter 2014 Results

KVISTGAARD, Denmark, May 14, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results...

Bavarian Nordic Announces First Patient Treated in a Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 in Bladder C...

KVISTGAARD, Denmark, April 28, 2014 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the first patient has now...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bavarian Nordic AS (PK) (BVNRY)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

BVNRY Actualités

Withdrawal of Registration Statement (rw)

Securities Registration (foreign Private Issuer) (f-1/a)

Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)

EDISON EQUITY RESEARCH - BAVARIAN NORDIC

Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Can...

EDISON EQUITY RESEARCH - BAVARIAN NORDIC

Bavarian Nordic Announces First Patient Treated in a Phase 1 Study of MVA-BN(r) Brachyury in Advanced Cancer

Bavarian Nordic Announces Appointment of Paul Chaplin, Ph.D. as President & CEO

Bavarian Nordic to Present Data Combining Its Cancer Immunotherapies With Immune Checkpoint Inhibitors at the 2014 ASCO Annua...

Bavarian Nordic Announces First Quarter 2014 Results

Bavarian Nordic Announces First Patient Treated in a Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 in Bladder C...

Bavarian Nordic Announces 2013 Full Year Results

Alliance For Biosecurity Elects Chief Executive Officers Of Bavarian Nordic And Elusys Therapeutics As New Co-Chairs

Notice of Effectiveness (effect)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Bavarian Nordic AS (PK) (BVNRY) Actualités

Bavarian Nordic AS (PK) (BVNRY)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

BVNRY Actualités

Withdrawal of Registration Statement (rw)

Securities Registration (foreign Private Issuer) (f-1/a)

Post-effective Amendment to a Previously Filed F-6. (f-6 Pos)

EDISON EQUITY RESEARCH - BAVARIAN NORDIC

Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Can...

EDISON EQUITY RESEARCH - BAVARIAN NORDIC

Bavarian Nordic Announces First Patient Treated in a Phase 1 Study of MVA-BN(r) Brachyury in Advanced Cancer

Bavarian Nordic Announces Appointment of Paul Chaplin, Ph.D. as President & CEO

Bavarian Nordic to Present Data Combining Its Cancer Immunotherapies With Immune Checkpoint Inhibitors at the 2014 ASCO Annua...

Bavarian Nordic Announces First Quarter 2014 Results

Bavarian Nordic Announces First Patient Treated in a Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 in Bladder C...

Bavarian Nordic Announces 2013 Full Year Results

Alliance For Biosecurity Elects Chief Executive Officers Of Bavarian Nordic And Elusys Therapeutics As New Co-Chairs

Notice of Effectiveness (effect)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités